

Appl. No. 10/692,338
Amendment dated March 10, 2007
Response to Office Action of February 20, 2007

REMARKS/ARGUMENTS

Applicants thank the Examiner for the withdrawal of the previous claim objections and rejections under 35 U.S.C. §103 (a).


The Examiner has provisionally rejected claims 1-3 and 6 on the ground of obviousness type double patenting based on copending Application No. 11/118,613. Attached hereto is a terminal disclaimer and fee obviating this provisional rejection, should the '613 application issue as a patent.

The Examiner has rejected claims 1-3 and 6 under 35 U.S.C. §112, second paragraph as being indefinite because the term "chronic administration" is not supported in the specification. Claims 1-3 and 6 have been amended to recite that the administration is to be continued for a period of at least one week. Support for this amendment can be found in the specification, page 13, line 15, which states that the subjects in the clinical trial supporting this invention were given ribose for three weeks.

The Examiner has rejected claims 2 and 3 as improperly dependent on amended claim 1 which now recites "consisting of." Claim 2 has been amended to incorporate all the limitations of claim 1, adding the recitation of an effective amount of a vasodilator. Claim 3 recites the vasodilators commonly used, the effective amount of each being commonly known to those skilled in the art. Applicant believes that those practicing this invention will select a vasodilator and dosage appropriate to each patient.

Applicants believe that with the current amendments and the terminal disclaimer, claims 1-3 and 6 are in condition for allowance and respectfully request that a timely Notice of Allowance be issued in this case.

Respectfully submitted,



Kathleen R. Terry, Attorney for Applicants
Reg. No. 31884
(651) 659-9819
krterry@visi.com

Kathleen R. Terry
Bionenergy, Inc.